Information Provided By:
Fly News Breaks for January 27, 2020
Jan 27, 2020 | 07:18 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $35 from $27 and reiterates an Overweight rating on the shares. The analyst has "enhanced conviction" in the potential magnitude and sustainability of growth in revenue and profitability of ENHANZE-driven milestones and royalties after hosting the company for investor meetings. The ENHANZE technology platform is gaining momentum and is now set to demonstrate its value-add with not one, but possibly two, high-profile approvals in 2020, Duncan tells investors in a research note.